Overview Dividends

(THRM) Gentherm - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US37253A1034

Climate Seats, Lumbar Massage, Battery Cooling, Patient Warming

Automotive Parts & Equipment
Market Cap in USD: 1,124m

IPO / Inception: 1993-06-10
Return 12m vs S&P 500: -19.6%

EPS (Earnings per Share)

EPS CAGR: -43.17%
EPS Trend: -8.2%

Last SUE: -2.80
Qual. Beats: 0

Revenue

Rev. CAGR: 12.25%
Rev. Trend: 76.1%

Last SUE: 0.82
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	38.2%
Value at Risk 5%th	54.8%
Relative Tail Risk	-12.93%

Reward TTM
Sharpe Ratio	-0.07
Alpha	-21.47
CAGR/Max DD	-0.29

Character TTM
Hurst Exponent	0.320
Beta	0.953
Beta Downside	0.798

Drawdowns 3y
Max DD	69.02%
Mean DD	38.48%
Median DD	35.97%

Description: THRM Gentherm November 17, 2025

Gentherm Inc. (NASDAQ: THRM) designs, develops, manufactures, and sells thermal-management and pneumatic-comfort technologies for both automotive and medical markets, operating through two primary segments: Automotive and Medical.

In the automotive space the company supplies climate-comfort systems such as seat heaters, steering-wheel heaters, blowers, thermoelectric devices, and pneumatic lumbar-massage solutions, plus related electronic control units (ECUs) and cable-assembly products that connect these components to vehicle power and data networks.

On the medical side, Gentherm offers patient temperature-management platforms-including the Blanketrol, Kool-Kit, Maxi-Therm Lite, WarmAir, and Hemotherm families-used for therapeutic hypothermia, normothermia, and peri-operative warming/cooling in intensive-care and surgical settings.

The firm serves light-vehicle OEMs and Tier-1 suppliers as well as hospitals and specialty-care providers. It was founded as Amerigon in 1991, renamed Gentherm in September 2012, and is headquartered in Northville, Michigan.

**Key data points (FY 2023)**: total revenue ≈ $1.2 billion, with the automotive segment contributing ~ 75 % and the medical segment ~ 25 %; operating margin hovered around 10 %; free cash flow exceeded $150 million, supporting ongoing R&D and acquisitions. **Sector drivers**: accelerating EV adoption (thermal-management demand projected to grow > 15 % YoY) and tighter cabin-temperature regulations in Europe and China are expanding the addressable market for seat-heating and cooling solutions. In the medical arena, an aging global population and increasing use of therapeutic hypothermia in cardiac arrest care are boosting demand for Gentherm’s temperature-control devices.

For a deeper quantitative view of Gentherm’s valuation metrics and scenario analysis, you may find ValueRay’s analyst toolkit a useful next step.

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (30.6m TTM) > 0 and > 6% of Revenue (6% = 87.9m TTM)

FCFTA 0.05 (>2.0%) and ΔFCFTA 1.02pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 26.32% (prev 25.27%; Δ 1.05pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.09 (>3.0%) and CFO 124.4m > Net Income 30.6m (YES >=105%, WARN >=100%)

Net Debt (-94.3m) to EBITDA (153.2m) ratio: -0.62 <= 3.0 (WARN <= 3.5)

Current Ratio 1.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (30.7m) change vs 12m ago -1.97% (target <= -2.0% for YES)

Gross Margin 24.13% (prev 25.62%; Δ -1.48pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 109.3% (prev 113.2%; Δ -3.92pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 7.24 (EBITDA TTM 153.2m / Interest Expense TTM 13.9m) >= 6 (WARN >= 3)

Altman Z'' 5.14

(A) 0.28 = (Total Current Assets 785.9m - Total Current Liabilities 400.3m) / Total Assets 1.38b

(B) 0.51 = Retained Earnings (Balance) 711.1m / Total Assets 1.38b

(D) 1.07 = Book Value of Equity 712.5m / Total Liabilities 663.4m

Total Rating: 5.14 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 64.20

1. Piotroski 5.50pt

2. FCF Yield 6.57%

3. FCF Margin 4.62%

4. Debt/Equity 0.08

5. Debt/Ebitda -0.62

6. ROIC - WACC (= -1.13)%

7. RoE 4.57%

8. Rev. Trend 76.11%

9. EPS Trend -8.24%

What is the price of THRM shares?

As of January 08, 2026, the stock is trading at USD 37.75 with a total of 134,000 shares traded.
Over the past week, the price has changed by +3.79%, over one month by +3.94%, over three months by +9.55% and over the past year by -4.65%.

Is THRM a buy, sell or hold?

Gentherm has received a consensus analysts rating of 3.83. Therefore, it is recommended to buy THRM.

Strong Buy: 2
Buy: 1
Hold: 3
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the THRM price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	45.6	20.8%
Analysts Target Price	45.6	20.8%
ValueRay Target Price	34.6	-8.4%

THRM Fundamental Data Overview January 06, 2026

Market Cap USD = 1.12b (1.12b USD * 1.0 USD.USD)
P/E Trailing = 37.202
P/E Forward = 14.3266
P/S = 0.7655
P/B = 1.5659
P/EG = 0.71
Beta = 1.381
Revenue TTM = 1.46b USD
EBIT TTM = 101.0m USD
EBITDA TTM = 153.2m USD
Long Term Debt = 189.0m USD (from longTermDebt, last quarter)
Short Term Debt = 10.3m USD (from shortTermDebt, last quarter)
Debt = 60.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -94.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.03b USD (1.12b + Debt 60.0m - CCE 154.2m)
Interest Coverage Ratio = 7.24 (Ebit TTM 101.0m / Interest Expense TTM 13.9m)
FCF Yield = 6.57% (FCF TTM 67.7m / Enterprise Value 1.03b)
FCF Margin = 4.62% (FCF TTM 67.7m / Revenue TTM 1.46b)
Net Margin = 2.09% (Net Income TTM 30.6m / Revenue TTM 1.46b)
Gross Margin = 24.13% ((Revenue TTM 1.46b - Cost of Revenue TTM 1.11b) / Revenue TTM)
Gross Margin QoQ = 23.81% (prev 23.93%)
Tobins Q-Ratio = 0.75 (Enterprise Value 1.03b / Total Assets 1.38b)
Interest Expense / Debt = 5.52% (Interest Expense 3.31m / Debt 60.0m)
Taxrate = 28.42% (5.93m / 20.9m)
NOPAT = 72.3m (EBIT 101.0m * (1 - 28.42%))
Current Ratio = 1.96 (Total Current Assets 785.9m / Total Current Liabilities 400.3m)
Debt / Equity = 0.08 (Debt 60.0m / totalStockholderEquity, last quarter 717.9m)
Debt / EBITDA = -0.62 (Net Debt -94.3m / EBITDA 153.2m)
Debt / FCF = -1.39 (Net Debt -94.3m / FCF TTM 67.7m)
Total Stockholder Equity = 670.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.22% (Net Income 30.6m / Total Assets 1.38b)
RoE = 4.57% (Net Income TTM 30.6m / Total Stockholder Equity 670.3m)
RoCE = 11.75% (EBIT 101.0m / Capital Employed (Equity 670.3m + L.T.Debt 189.0m))
RoIC = 8.12% (NOPAT 72.3m / Invested Capital 890.4m)
WACC = 9.25% (E(1.12b)/V(1.18b) * Re(9.53%) + D(60.0m)/V(1.18b) * Rd(5.52%) * (1-Tc(0.28)))
Discount Rate = 9.53% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.28%
[DCF Debug] Terminal Value 73.65% ; FCFE base≈60.8m ; Y1≈63.0m ; Y5≈71.9m
Fair Price DCF = 31.98 (DCF Value 976.1m / Shares Outstanding 30.5m; 5y FCF grow 3.83% → 3.0% )
EPS Correlation: -8.24 | EPS CAGR: -43.17% | SUE: -2.80 | # QB: 0
Revenue Correlation: 76.11 | Revenue CAGR: 12.25% | SUE: 0.82 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.55 | Chg30d=+0.048 | Revisions Net=+2 | Analysts=4
EPS next Year (2026-12-31): EPS=2.64 | Chg30d=+0.058 | Revisions Net=+0 | Growth EPS=+10.1% | Growth Revenue=+2.5%

Additional Sources for THRM Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle